SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis
Open Access
- 23 August 2022
- journal article
- research article
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 33 (6) , e75
Abstract
Zhu Y, et al. J Gynecol Oncol. 2022 Aug;33:e75. https://doi.org/10.3802/jgo.2022.33.e75Keywords
This publication has 34 references indexed in Scilit:
- The landscape of long noncoding RNAs in the human transcriptomeNature Genetics, 2015
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Management of recurrent epithelial ovarian cancer2014
- Scaffold function of long non-coding RNA HOTAIR in protein ubiquitinationNature Communications, 2013
- IGF2 and cancerEndocrine-Related Cancer, 2013
- Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1)Hepatology, 2013
- Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?Cellular and Molecular Life Sciences, 2012
- Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinomaEuropean Archives of Oto-Rhino-Laryngology, 2010
- Advanced ovarian cancer. Carboplatin versus cisplatin.1993
- Carboplatin versus cisplatinAnnals of Oncology, 1993